BioCentury | Apr 15, 2013
Company News

Rhone-Poulenc Rorer management update

Rhone-Poulenc Rorer, Collegeville, Penn. Business: Biopharmaceuticals Promoted: Thierry Soursac to SVP of RPR Research, while remaining general manager of the RPR Gencell division; Francois Meyer to VP of worldwide research, while remaining head of discovery...
BioCentury | Apr 15, 2013
Clinical News

Noven, RPR Japan regulatory update

...RPR Japan, the Japanese affiliate of Rhone-Poulenc Rorer Inc. , filed a PLA in Japan for Menorest, a...
BioCentury | Apr 15, 2013
Company News

Synbiotics, Rhone Merieux deal

...a definitive agreement to acquire the veterinary diagnostics business of Rhone Merieux, a division of Rhone-Poulenc Rorer Inc....
BioCentury | Apr 15, 2013
Company News

Introgen, Rhone-Poulenc Rorer deal

...Europe and other markets. Introgen retains North American manufacturing rights. Introgen Therapeutics Inc., Austin, Tex. Rhone-Poulenc Rorer Inc....
BioCentury | Dec 8, 2008
Company News

Vical, Rhone-Poulenc Rorer deal

...$9 million in milestones, and is eligible for royalties. Vical Inc. (VICL), San Diego, Calif. Rhone-Poulenc Rorer Inc....
BioCentury | Dec 4, 2006
Strategy

PER.C6 perseverance

...Somatix, SyStemix and Genetic Therapy Inc. , companies that had huge relationships with Sandoz and Rhone-Poulenc Rorer...
...thought the value of PER.C6 might lie." Brus secured the first two customers for PER.C6: Rhone-Poulenc Rorer...
BioCentury | Oct 16, 2006
Finance

Ebb & Flow

Like many top tier biotechs, Genentech (DNA) does not provide any product-specific sales guidance, leaving Street forecasters to take their best guess at upcoming sales and earnings. While DNA may or may not care whether...
BioCentury | Sep 25, 2006
Finance

Ebb & Flow

...of the IP, invalidating claims of inventorship by a predecessor of sanofi-aventis Group (Euronext:SAN; SNY), Rhone-Poulenc Rorer Inc....
BioCentury | Sep 25, 2006
Strategy

3-card monte

...treat cancer - was assigned to a group of scientists affiliated with a predecessor of Rhone-Poulenc Rorer Inc....
BioCentury | Jan 27, 2003
Company News

Ribapharm board of directors update

...Costa Mesa, Calif. Business: Infectious diseases, Cancer Appointed: Daniel Paracka, former SVP and CFO of Rhone-Poulenc Rorer...
Items per page:
1 - 10 of 279
BioCentury | Apr 15, 2013
Company News

Rhone-Poulenc Rorer management update

Rhone-Poulenc Rorer, Collegeville, Penn. Business: Biopharmaceuticals Promoted: Thierry Soursac to SVP of RPR Research, while remaining general manager of the RPR Gencell division; Francois Meyer to VP of worldwide research, while remaining head of discovery...
BioCentury | Apr 15, 2013
Clinical News

Noven, RPR Japan regulatory update

...RPR Japan, the Japanese affiliate of Rhone-Poulenc Rorer Inc. , filed a PLA in Japan for Menorest, a...
BioCentury | Apr 15, 2013
Company News

Synbiotics, Rhone Merieux deal

...a definitive agreement to acquire the veterinary diagnostics business of Rhone Merieux, a division of Rhone-Poulenc Rorer Inc....
BioCentury | Apr 15, 2013
Company News

Introgen, Rhone-Poulenc Rorer deal

...Europe and other markets. Introgen retains North American manufacturing rights. Introgen Therapeutics Inc., Austin, Tex. Rhone-Poulenc Rorer Inc....
BioCentury | Dec 8, 2008
Company News

Vical, Rhone-Poulenc Rorer deal

...$9 million in milestones, and is eligible for royalties. Vical Inc. (VICL), San Diego, Calif. Rhone-Poulenc Rorer Inc....
BioCentury | Dec 4, 2006
Strategy

PER.C6 perseverance

...Somatix, SyStemix and Genetic Therapy Inc. , companies that had huge relationships with Sandoz and Rhone-Poulenc Rorer...
...thought the value of PER.C6 might lie." Brus secured the first two customers for PER.C6: Rhone-Poulenc Rorer...
BioCentury | Oct 16, 2006
Finance

Ebb & Flow

Like many top tier biotechs, Genentech (DNA) does not provide any product-specific sales guidance, leaving Street forecasters to take their best guess at upcoming sales and earnings. While DNA may or may not care whether...
BioCentury | Sep 25, 2006
Finance

Ebb & Flow

...of the IP, invalidating claims of inventorship by a predecessor of sanofi-aventis Group (Euronext:SAN; SNY), Rhone-Poulenc Rorer Inc....
BioCentury | Sep 25, 2006
Strategy

3-card monte

...treat cancer - was assigned to a group of scientists affiliated with a predecessor of Rhone-Poulenc Rorer Inc....
BioCentury | Jan 27, 2003
Company News

Ribapharm board of directors update

...Costa Mesa, Calif. Business: Infectious diseases, Cancer Appointed: Daniel Paracka, former SVP and CFO of Rhone-Poulenc Rorer...
Items per page:
1 - 10 of 279